Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ErVaccine T cell therapy (Ovarian Cancer)
- Development stage
- Preclinical
- Lead developer
- ErVimmune
- Modality
- Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ErVaccine's T cell-based therapy is an experimental adoptive cell therapy designed for the treatment of advanced or metastatic ovarian cancer. The therapy targets non-conventional antigens (NCAs) derived from Human Endogenous Retroviruses (HERVs), which are ancestral viral elements integrated into the human genome. While typically silent in healthy tissues, these HERV sequences can be reactivated and expressed in malignant cells, providing a unique set of tumor-specific targets. By utilizing T cells engineered or selected to recognize these HERV-derived epitopes, the treatment aims to provide a precise immune attack against ovarian cancer cells, potentially overcoming the limitations of traditional therapies. The program is currently in the preclinical development stage under ErVimmune (formerly ErVaccine).
- Other names
- HERV-targeted T cell therapyErVaccine ovarian cancer cell therapyErVaccine-HERVs-non-conventional antigens-T cell-based therapy
02
Targets
Human endogenous retrovirus-derived peptide–human leukocyte antigen complex
Beyond the preview
Go deeper on ErVaccine T cell therapy (Ovarian Cancer).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ErVaccine T cell therapy (Ovarian Cancer).